Grenoble: a start-up is developing a pain-relieving bracelet against fibromyalgia

Clinical trials will soon begin to test the effectiveness of a pain-relieving bracelet designed by a Grenoble-based company. The device would be effective on several types of chronic pain, including fibromyalgia.

The Grenoble-based start-up Remedee has developed a bracelet that it presents as “unique in the world”. The device, a pain-relieving stimulator, resembles a watch strap and can be operated at will. It aims to reduce the use of drugs against chronic pain such as fibromyalgia, a pathology from which women mainly suffer and which can be disabling.

“It is important to be able to use it anytime, anywhere. It was really a key element in the design of the device,” says David Crouzier, co-founder of the company. Based on advances in microelectronics, the bracelet stimulates a chemical substance in the brain: endorphin, nicknamed “the hormone of happiness”.

“The chips are placed on the surface of the wrist. They will emit a specific radiation which will activate the nerve endings under the skin. It is the first element of the stimulation of endorphins. It will then carry a message to the brain, triggering the production of these endorphins which are natural analgesics, ” explains David Crouzier.

The Remedee start-up was created in 2016, based on research from CEA Grenoble . It took him four years to develop his innovation which rhymes with miniaturization. It is based on microelectronics thanks to four silicon chips that use electromagnetic waves.https://www.youtube.com/embed/bKJ3o-kp9dMGrenoble: a start-up is developing a pain-relieving bracelet against fibromyalgia

Clinical trials soon to be launched

“These are silicon components that were designed by Remedee with CEA Grenoble and STMicroelectronics. They will emit millimeter radiation at 60 gigahertz (GHz) which will be sent in the direction of the nerve endings” , summarizes Michael Foerster, co-founder of the company.

Thirty people were recruited to develop the stimulator. And to validate this, clinical trials targeting several types of chronic pain will be launched, in particular with the Grenoble University Hospital. “From the moment we have the clinical results, we can think of obtaining the medical CE marking: the medical device as such that will allow us to put the solution on the market. We can imagine that this will happen sooner rather than later. end of 2022 “ , estimates Jacques Husser, co-founder and CEO of the company.

In addition to fibromyalgia, the start-up targets migraine and osteoarthritis. The market is large, as nearly 30% of the world’s population suffers from chronic pain.

Share with yours friends

Leave a Reply

Your email address will not be published. Required fields are marked *

error: Content is protected !!